September 03, 2025 16:57 ET | Source: Sotera Health Services, LLC CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health…
September 03, 2025 16:57 ET | Source: vTv Therapeutics Inc. HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv…
September 02, 2025 21:33 ET | Source: Mineralys Therapeutics, Inc. RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics,…
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from…
September 02, 2025 17:00 ET | Source: ZENTALIS PHARMACEUTICALS SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc.…
Randomized multi-center study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with moderately active rheumatoid arthritis…
New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor…
In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue…
ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis…
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective…